Solé Carla, Arnaiz Esther, Lawrie Charles H
Molecular Oncology Group, Biodonostia Research Institute, San Sebastián, Spain.
Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
Biomark Insights. 2018 Oct 16;13:1177271918806840. doi: 10.1177/1177271918806840. eCollection 2018.
B-cell lymphomas represent a diverse group of neoplasms classified primarily by histopatholgy and are often challenging to accurately diagnose. Despite having been recognized less than 20 years ago, microRNAs (miRNAs) have emerged as one of the most promising class of cancer molecular biomarkers and are particularly attractive as they can be readily detected in formalin-fixed paraffin-embedded biopsy material and biological fluids such as blood. Many of the identified B-cell lymphoma miRNA biomarkers also play crucial regulatory roles in normal B-cell development. Below we consider the identity, function, and biomarker potential of miRNAs in B-cell lymphoma and most importantly the barriers that remain to be overcome if they are really to become part of routine clinical practice.
B细胞淋巴瘤是一组主要根据组织病理学分类的多样化肿瘤，准确诊断往往具有挑战性。尽管微小RNA（miRNA）在不到20年前才被认识到，但它们已成为最有前景的一类癌症分子生物标志物，尤其具有吸引力的是，它们可以很容易地在福尔马林固定石蜡包埋的活检材料和血液等生物体液中检测到。许多已鉴定出的B细胞淋巴瘤miRNA生物标志物在正常B细胞发育中也发挥着关键的调节作用。下面我们将探讨miRNA在B细胞淋巴瘤中的特性、功能和作为生物标志物的潜力，最重要的是，如果它们真的要成为常规临床实践的一部分，仍有待克服的障碍。
